[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623620":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":29,"responsibleParty":96,"collaborators":10,"id":98,"slug":10,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":16,"eligibilityCriteria":103,"healthyVolunteers":99,"sex":104,"minAge":105,"maxAge":10,"enrollmentInfo":106,"targetDuration":109,"studyType":110,"phases":10,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"Fundación EPIC","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Coronary Artery Disease (CAD)",null,[12],"Device: LONG NAGOMI",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DEVICE","LONG NAGOMI","Patients in whom treatment with long nagomi has been attempted",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"TAMARA GARCIA CAMARERO, MD, PhD","CONTACT","0034615420460","tgcamarero@gmail.com",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"FUNDACION EPIC","00987876135","iepic@fundacionepic.org",[30,42,51,60,69,78,87],{"facility":31,"status":32,"city":33,"state":10,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":10},"Hospital Universitario de Cabueñes","RECRUITING","Cabueñes","33394","Spain",{"type":37,"coordinates":38},"Point",[39,40],-5.60569,43.52347,{"lat":40,"lon":39},{"facility":43,"status":32,"city":44,"state":10,"zip":45,"country":35,"cosmosGeoPoint":46,"geoPoint":50,"contacts":10},"Hospital General Universitario de Elche","Elche","03203",{"type":37,"coordinates":47},[48,49],-0.70107,38.26218,{"lat":49,"lon":48},{"facility":52,"status":32,"city":53,"state":10,"zip":54,"country":35,"cosmosGeoPoint":55,"geoPoint":59,"contacts":10},"Hospital Universitario Juan Ramón Jiménez","Huelva","21005",{"type":37,"coordinates":56},[57,58],-6.94004,37.26638,{"lat":58,"lon":57},{"facility":61,"status":32,"city":62,"state":10,"zip":63,"country":35,"cosmosGeoPoint":64,"geoPoint":68,"contacts":10},"Hospital Universitario de Leon","León","24008",{"type":37,"coordinates":65},[66,67],-5.57032,42.60003,{"lat":67,"lon":66},{"facility":70,"status":32,"city":71,"state":10,"zip":72,"country":35,"cosmosGeoPoint":73,"geoPoint":77,"contacts":10},"Hospital Universitario Regional de Málaga","Málaga","29010",{"type":37,"coordinates":74},[75,76],-4.42034,36.72016,{"lat":76,"lon":75},{"facility":79,"status":32,"city":80,"state":10,"zip":81,"country":35,"cosmosGeoPoint":82,"geoPoint":86,"contacts":10},"Hospital Universitario de Navarra","Pamplona","31008",{"type":37,"coordinates":83},[84,85],-1.64323,42.81687,{"lat":85,"lon":84},{"facility":88,"status":32,"city":89,"state":10,"zip":90,"country":35,"cosmosGeoPoint":91,"geoPoint":95,"contacts":10},"Hospital Universitario Marqués de Valdecilla","Santander","39008",{"type":37,"coordinates":92},[93,94],-3.80493,43.46589,{"lat":94,"lon":93},{"type":97,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100623620",false,"NCT07399002","LONG NAGOMI™ PMCF STUDY","Long Coronary Lesions: Safety and Performance of the Ultimaster Nagomi™ Stent in This Setting With a One-to-one Approach -One Lesion, One Stent- LONG NAGOMI™ PMCF STUDY","Inclusion Criteria:\n\n* Patients who meet ALL inclusion criteria will be included:\n* Patients aged ≥ 18 years AND;\n* Patients who according to standard practice of the hospital are amenable to PCI as indicated and considered adequate according to the European clinical practice guidelines on coronary revascularization AND;\n* Patients with at least one lesion fulfilling the \"long lesion criteria\" suitable for a single stent approach AND;\n* Patients who have been informed of the characteristics of the study and have provided written informed consent AND;\n* Intention to treat all lesions with the Ultimaster Nagomi™ stent\n\nExclusion Criteria:\n\n* Patients must not meet any of the following exclusion criteria:\n* Patients who expressly decline to participate in the study.\n* Pregnant or breastfeeding women.\n* Patients with acute coronary syndrome (ACS) under conditions of cardiogenic shock (Killip class 4).\n* Patients with contraindications or hypersensitivity to sirolimus.\n* Patients with a life expectancy of less than 2 years.\n* Patients in whom any surgery requiring general anesthesia is planned, comorbidity or indication likely necessitating the discontinuation of dual anti-platelet therapy before the recommended duration of dual anti-platelet therapy per the ESC or national guidelines.\n* Patients included in other clinical trials that did not reach the primary objective.","ALL","18 Years",{"count":107,"type":108},1039,"ESTIMATED","12 Months","OBSERVATIONAL","The study is designed as a prospective, multi-center, observational PMCF (post-market clinical follow-up) study of the Ultimaster Nagomi™ \\_stent (lengths of 38, 44 and 50 mm) in the treatment of coronary artery disease according to the indications approved in the CE marking.",[113,114],"Coronary Artery Disease","Ischemic Heart Disease",[116,117],"MDR (Medical Device Regulations)","PMCF (Post-Market Clinical Follow-up)","2026-06-19",{"date":120,"type":121},"2026-06-23","ACTUAL",{"date":123,"type":121},"2026-02-27",{"date":125,"type":108},"2029-01-01",{"name":5,"class":6},7]